
Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q1 earnings of $128.08 million, an increase from Q4 of 138.64%. Sales dropped to $562.00 million, a 2.43% decrease between quarters. In Q4, Royalty Pharma brought in $576.00 million in sales but only earned $53.67 million.